SCHEMBL4835480

SCHEMBL4835480

CN(C)CCOC(=O)c1ccc(N)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 1.00
MAOA P21397 3/20 0.71
TSHR P16473 2/20 0.71
CYP2D6 P10635 2/20 0.71
HRH3 Q9Y5N1 2/20 0.71
HTR3A P46098 1/20 0.71
BLM P54132 2/20 0.69
NPSR1 Q6W5P4 1/20 0.69
ALDH1A1 P00352 3/20 0.63
MAPT P10636 2/20 0.63
LMNA P02545 6/20 0.63
CYP1A2 P05177 4/20 0.63
CYP3A4 P08684 3/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
PDE4D Q08499 1/20 0.63
SCN1A P35498 4/20 0.61
SCN2A Q99250 4/20 0.61
SCN3A Q9NY46 4/20 0.61
GAA P10253 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8963488 0.91 PHLPP2 (0.83) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL11641497 0.90 PHLPP2 (0.82) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL14218445 0.89 PHLPP2 (0.79) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL31122273 0.88 PHLPP2 (0.78) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL21499736 0.85 MAOA (0.75) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL1107147 0.84 PHLPP2 (0.73) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL8639938 0.84 PHLPP2 (0.73) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL8963375 0.84 PHLPP2 (0.73) PHLPP2MAOATSHRCYP2D6HRH3
SCHEMBL25239695 0.83 CYP2D6 (0.94) PHLPP2MAOATSHRCYP2D6HRH3
Procaine SCHEMBL3524 0.83 CYP2D6 (1.00) PHLPP2MAOATSHRCYP2D6HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390597-A Preparation method of tetracaine crystal form 长沙晶易医药科技股份有限公司 2025-02-07 CN disclosed
US-7332489-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2008-02-19 US disclosed
EP-1560817-A1 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS Reddy US Therapeutics, Inc. (US) 2005-08-10 EP disclosed
EP-1436266-A4 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS INC (US) 2004-12-22 EP disclosed
WO-2004026844-A9 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS INC (US) 2004-11-11 WO disclosed
EP-1436266-A2 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS Reddy US Therapeutics, Inc. (US) 2004-07-14 EP disclosed
WO-2004026844-A1 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS, INC. (US) 2004-04-01 WO disclosed
WO-2003024926-A2 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS, INC. (US) 2003-03-27 WO disclosed
US-5453532-A Cooling and crystallization LEONIDOV NIKOLAI B (RU) 1995-09-26 US disclosed
US-5403951-A Crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride, method for production thereof and pharmaceutical preparation for anaesthesia of eyes, based thereon LEONIDOV NIKOLAI B (RU) 1995-04-04 US disclosed